Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
NanoViricides, Inc. (NYSE American:NNVC) (the 'Company') declared today that it is ready to fight the bird flu with its revolutionary ...
EurekAlert!2 天
Innovative dual-target drug may lead to new investigational approach for breast cancer patients
Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
manilatimes3 天
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in ...
FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...
FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to ...
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for ...
News Medical7 天
New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product ...
This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...